Multi-organ MRI for the quantification of tissue characteristics from six organs

What is CoverScan?

CoverScan is a tool for quantifying the characteristics of six different organs using a single noninvasive scan, enabling clinicians to visualize and assess multi-organ health. Referring clinicians are provided with a report of 49 metrics from multiparametric MR data for easy assessment of multi-organ function relative to reference ranges.

The information provided by CoverScan, in conjunction with other tests and clinical evaluation of the patient, may form part of a clinical decision-making pathway and enable physicians to make more informed clinical decisions for patients. Importantly, repeated analyses using CoverScan may aid clinicians to monitor patients and personalize treatments.

CoverScan is an advanced cloud-based software suite, delivered as a software as a service solution, and uses existing clinical MR infrastructure.

In the U.K., the multiparametric multi-organ imaging technology is available as a tool to aid diagnoses for patients with multi-systemic diseases such as long COVID (1) or insulin resistance (e.g., metabolic syndrome and diabetes mellitus). It has been available within the U.K.’s NHS since January 2021, under the MHRA’s temporary authorization, in response to the COVID-19 pandemic. CoverScan 1.0 (Siemens 1.5T and GE 1.5T) received full UKCA clearance in May 2022.

In the U.S., CoverScan 1.2 (Siemens 1.5T scanner) has been available clinically, with FDA 510(k) clearance since May 2022.

Learn more
about CoverScan

Publications

A curated collection of scientific papers showcasing the diagnostic value and clinical utility of CoverScan.

Learn More

Promotional Material

Download CoverScan brochures, clinical overviews, and educational resources for healthcare professionals.

Learn More

Download your version of
“A Guide to Interpreting Multi-Organ
Multiparametric MRI Tissue Characterization”

View Product Guides

References

Dennis, A., et al. (2021). Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open, 113, e048391.

Connect with Our Team

Do you have questions about our clinical or pharmaceutical solutions?

Our team is here to help. Simply share your question and your email address, and a member of the team will get back to you directly.